|
Ifosfamide in Treating Patients With Meningeal Tumors Clinical Trials Data presented on Clinical Trials Search is not meant to be a substitute for qualified medical advice, visits or professional assistance with a genuine dr.. We are not doctors. Always consult your mD about Ifosfamide in Treating Patients With Meningeal Tumors conditions. Clinical Trials Search.org is a site devoted to listing clinical research studies in human subjects. Ifosfamide in Treating Patients With Meningeal Tumors Clinical research trials and Ifosfamide in Treating Patients With Meningeal Tumors medical trials take place in many of places throughout the U.S.A.. A clinical trial or clinical study is a research project with human volunteer subjects. Clinical drug trials and pharmaceutical clinical trials usually evaluate the effectiveness of new does drugs. The purpose of the studies / projects is to solve specific human healthcare questions. Clinical trials are a popular way for mDs, government agencies, and private sector companies to find cures for all varieties of conditions, like Ifosfamide in Treating Patients With Meningeal Tumors. Ifosfamide in Treating Patients With Meningeal Tumors Clinical Trials and other clinical trials allow for volunteers to have health treatment options before they are available to the masses. Many times the human subjects acquire professional assistance for free of charge, and sometimes they are compensated for their time. Occasionally there is a cost for a Ifosfamide in Treating Patients With Meningeal Tumors clinical trial. Test subjects typically obtain the finest healthcare available for their Ifosfamide in Treating Patients With Meningeal Tumors condition. Dangers are a reality, nevertheless, and might include additional or frequent doctor trips, medical dangers (possibly life-jeopardising), and/or the treatment being ineffectual. Trials are federally regulated with strict guidelines to protect clinical trials patients.
|
|
|
|
|
|
|
Home > "I" Clinical Trials Conditions > Ifosfamide in Treating Patients With Meningeal Tumors  Ifosfamide in Treating Patients With Meningeal Tumors
Ifosfamide in Treating Patients With Meningeal Tumors
For Condition: adult malignant meningioma,adult fibrosarcoma,adult rhabdomyosarcoma,adult brain malignant hemangiopericytoma,Chondrosarcoma,adult leiomyosarcoma
Status: Suspended
Sponsor(s): Southwest Oncology Group , National Cancer Institute (NCI),Eastern Cooperative Oncology Group
Synopsis: RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. PURPOSE: Phase II trial to study the effectiveness of ifosfamide in treating patients with meningeal tumors that have recurred or that cannot be removed surgically.
Details: OBJECTIVES: - Estimate failure free survival, overall survival, and response in patients with residual or recurrent/progressive aggressive meningeal tumors (malignant meningioma, hemangiopericytoma, and primary nervous system sarcoma) treated with ifosfamide. - Evaluate toxicities of ifosfamide in this patient population. OUTLINE: All patients receive ifosfamide IV continuously over 72 hours on days 1-3 of each 21 day treatment course. Patients are evaluated for response/progression after every 2 courses. Patients with stable disease receive up to 8 courses of therapy. Treatment continues in the absence of disease progression or unacceptable toxicity. Patients are followed every 3 months for 1 year, then every 6 months thereafter. PROJECTED ACCRUAL: Approximately 35 patients will be accrued for this study.
Eligibility:
Study Type: Interventional, Treatment
Minimum Age/Maximum Age: 18 Years/
Genders: Both
Protocol Entry Criteria: DISEASE CHARACTERISTICS: - Histologically proven recurrent or unresectable: - Malignant meningioma - Intracranial hemangiopericytoma - Primary central nervous system sarcoma, including: - Fibrosarcoma - Rhabdomyosarcoma - Chondrosarcoma - Leiomyosarcoma - Measurable or evaluable disease on CT or MRI scan - Persistent disease following biopsy or incomplete resection OR - Recurrent disease following complete resection - No benign meningioma - No prior or current systemic sarcoma PATIENT CHARACTERISTICS: Age: - 18 and over Performance status: - SWOG 0-2 Life expectancy: - Not specified Hematopoietic: - WBC at least 3,000/mm^3 - Absolute granulocyte count at least 1,500/mm^3 - Platelet count at least 100,000/mm^3 Hepatic: - Not specified Renal: - Creatinine no greater than 2.0 mg/dL Cardiovascular: - No myocardial infarction within the past 3 months - No active angina - No unstable heart rhythms - No congestive heart failure Other: - HIV negative - No allergy to study drugs - No serious concurrent medical or psychiatric illness - No uncontrolled peptic ulcer disease - No prior malignancy within past 5 years except adequately treated: - Basal or squamous cell carcinoma of the skin - Carcinoma in situ of the cervix - Not pregnant or nursing - Effective contraception required of fertile patients PRIOR CONCURRENT THERAPY: - Recovered from toxic effects of prior therapy and/or from postoperative complications Biologic therapy: - Not specified Chemotherapy: - No prior ifosfamide - No other concurrent chemotherapy Endocrine therapy: - No concurrent hormonal therapy (except estrogen replacement therapy) - Corticosteroids allowed if dose is stable or decreasing Radiotherapy: - At least 4 weeks since prior radiotherapy - Progressive disease following radiation required - No concurrent radiotherapy Surgery: - See Disease Characteristics
Total Enrollment:
Location and Contact Information:
Overall Study Official:
LeslieMcAllister, Study Chair, Neurological Clinic
Mayo Clinic Cancer Center
Rochester, Minnesota, 55905
United States
CCOP - Marshfield Medical Research and Education Foundation
Marshfield, Wisconsin, 54449
United States
Iowa Lutheran Hospital
Des Moines, Iowa, 50316-2301
United States
Veterans Affairs Medical Center - Milwaukee (Zablocki)
Milwaukee, Wisconsin, 53295
United States
CCOP - Ochsner
New Orleans, Louisiana, 70121
United States
CCOP - Kalamazoo
Kalamazoo, Michigan, 49007-3731
United States
CCOP - MainLine Health
Wynnewood, Pennsylvania, 19096
United States
Iowa Methodist Medical Center
Des Moines, Iowa, 50309
United States
Drexel University Hospital
Philadelphia, Pennsylvania, 19102-1192
United States
Fox Chase Cancer Center
Philadelphia, Pennsylvania, 19111
United States
Veterans Affairs Medical Center - San Juan
San Juan, , 00927-5800
Puerto Rico
CCOP - Northern New Jersey
Hackensack, New Jersey, 07601
United States
Ireland Cancer Center
Cleveland, Ohio, 44106-5065
United States
CCOP - Columbus
Columbus, Ohio, 43206
United States
CCOP - Iowa Oncology Research Association
Des Moines, Iowa, 50309-1016
United States
Tuft-New England Medical Center
Boston, Massachusetts, 02111
United States
CCOP - Colorado Cancer Research Program, Incorporated
Denver, Colorado, 80224
United States
Milton S. Hershey Medical Center
Hershey, Pennsylvania, 17033-0850
United States
CCOP - Carle Cancer Center
Urbana, Illinois, 61801
United States
City of Hope Comprehensive Cancer Center
Duarte, California, 91010-3000
United States
Instituto de Enfermedades Neoplasicas
Lima, , 34
Peru
CCOP - Cedar Rapids Oncology Project
Cedar Rapids, Iowa, 52403-1206
United States
Albert Einstein Clinical Cancer Center
Bronx, New York, 10461
United States
Alegent Health-Midlands Community Hospital
Papillion, Nebraska, 68128-4157
United States
CCOP - Scottsdale Oncology Program
Scottsdale, Arizona, 85259-5404
United States
Veterans Affairs Medical Center - Minneapolis
Minneapolis, Minnesota, 55417-2399
United States
University of Pittsburgh Cancer Institute
Pittsburgh, Pennsylvania, 15236
United States
CCOP - Geisinger Clinic and Medical Center
Danville, Pennsylvania, 17822-2001
United States
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Baltimore, Maryland, 21231
United States
CCOP - Oklahoma
Tulsa, Oklahoma, 74136
United States
Veterans Affairs Medical Center - Gainesville
Gainesville, Florida, 32608-1197
United States
Veterans Affairs Medical Center - Indianapolis (Roudebush)
Indianapolis, Indiana, 46202
United States
Veterans Affairs Medical Center - Atlanta (Decatur)
Decatur, Georgia, 30033
United States
CCOP - Missouri Valley Cancer Consortium
Omaha, Nebraska, 68106
United States
CCOP - Christiana Care Health Services
Newark, Delaware, 19713
United States
H. Lee Moffitt Cancer Center and Research Institute
Tampa, Florida, 33612-9497
United States
Mercy Medical Center
Des Moines, Iowa, 50314
United States
Indiana University Cancer Center
Indianapolis, Indiana, 46202-5289
United States
CCOP - Sioux Community Cancer Consortium
Sioux Falls, South Dakota, 57104
United States
MBCCOP - San Juan
San Juan, , 00927-5800
Puerto Rico
San Juan City Hospital
San Juan, , 00936-7344
Puerto Rico
Veterans Affairs Medical Center - East Orange
East Orange, New Jersey, 07019
United States
Veterans Affairs Medical Center - Fargo
Fargo, North Dakota, 58102
United States
University of Wisconsin Comprehensive Cancer Center
Madison, Wisconsin, 53792-0001
United States
Kimmel Cancer Center of Thomas Jefferson University - Philadelphia
Philadelphia, Pennsylvania, 19107-5541
United States
CCOP - St. Vincent Hospital Cancer Center, Green Bay
Green Bay, Wisconsin, 54307-3453
United States
Veterans Affairs Medical Center - Palo Alto
Palo Alto, California, 94304-1290
United States
CCOP - Evanston
Evanston, Illinois, 60201
United States
University of Minnesota Cancer Center
Minneapolis, Minnesota, 55455
United States
Veterans Affairs Medical Center - New York
New York City, New York, 10010
United States
NYU School of Medicine's Kaplan Comprehensive Cancer Center
New York City, New York, 10016
United States
Veterans Affairs Medical Center - Brooklyn
Brooklyn, New York, 11209
United States
CCOP - Merit Care Hospital
Fargo, North Dakota, 58122
United States
Veterans Affairs Medical Center - Tampa (Haley)
Tampa, Florida, 33612
United States
Emory University Hospital - Atlanta
Atlanta, Georgia, 30322
United States
Veterans Affairs Medical Center - Madison
Madison, Wisconsin, 53705
United States
Beth Israel Deaconess Medical Center
Boston, Massachusetts, 02215
United States
Cleveland Clinic Taussig Cancer Center
Cleveland, Ohio, 44195
United States
CCOP - Central Illinois
Decatur, Illinois, 62526
United States
CCOP - Michigan Cancer Research Consortium
Ann Arbor, Michigan, 48106
United States
Stanford University Medical Center
Stanford, California, 94305-5216
United States
Cancer Institute of New Jersey
New Brunswick, New Jersey, 08903
United States
Veterans Affairs Medical Center - Pittsburgh
Pittsburgh, Pennsylvania, 15240
United States
James P. Wilmot Cancer Center
Rochester, New York, 14642
United States
Medical College of Wisconsin Cancer Center
Milwaukee, Wisconsin, 53226-3596
United States
Westmead Hospital
Westmead, New South Wales, 2145
Australia
MBCCOP - LSU Health Sciences Center
New Orleans, Louisiana, 70112
United States
CCOP - Southern Nevada Cancer Research Foundation
Las Vegas, Nevada, 89106
United States
MBCCOP - University of New Mexico HSC
Albuquerque, New Mexico, 87131
United States
CCOP - Illinois Oncology Research Association
Peoria, Illinois, 61602
United States
Additional Information:
Study ID Numbers: CDR0000066225; SWOG-S9624,E-S9624,NABTT-S9624
Study Start Date:
Record last reviewed: September 2003
Additional information available at: clinicaltrials.gov
Clinicaltrials.gov Reference link: NCT00003292
Other Adult Rhabdomyosarcoma Studies:
1. Ifosfamide in Treating Patients With Meningeal Tumors
Related Studies:
Other adult rhabdomyosarcoma Clinical Trials
Other Pennsylvania Clinical Trials
Other Pittsburgh Clinical Trials
Ifosfamide in Treating Patients With Meningeal Tumors
|
|
|
|
|
|
|
|
